Literature DB >> 34018092

CircRNA VIM silence synergizes with sevoflurane to inhibit immune escape and multiple oncogenic activities of esophageal cancer by simultaneously regulating miR-124/PD-L1 axis.

Cao Gao1, Yan-Jie Xu2, Lei Qi3, Ya-Fei Bao4, Lei Zhang4, Liang Zheng5.   

Abstract

BACKGROUND: Circular RNA of vimentin (circ-VIM) is a predictor for poor prognosis of acute myeloid leukemia, but we had little information on its function in esophageal cancer (EC). Here we examined the effects of circ-VIM together with sevoflurane on immune escape and multiple oncogenic activities of EC.
METHODS: Bioinformatic tools, luciferase assay, and RNA immunoprecipitation were used to examine regulations between circ-VIM, miR-124-3p (miR-124), and PD-L1. CCK-8, wound healing, and Transwell assays were used to measure cell proliferation, migration, and invasion, respectively. The impacts of EC cells on cytotoxicity, proliferation, and apoptosis of CD8+ T cells were examined using LDH assay, CFSE staining, and Annexin V/PI staining, respectively. The in vivo tumorigenesis and lung metastases were assessed using xenograft model and tail vein injection of EC cells.
RESULTS: Significant upregulation of circ-VIM and PD-L1 and downregulation of miR-124 were detected in EC tissues or cells. Circ-VIM sponged miR-124 and released its suppression on the downstream target PD-L1. Sevoflurane, independent of circ-VIM, also upregulated miR-124 to lower PD-L1 expression. By modulating miR-124/PD-L1 axis, silencing circ-VIM and applying sevoflurane both inhibited immune escape and multiple oncogenic activities of EC in vitro, and suppressed xenograft growth and lung metastases in vivo. The inactivation of Ras/ERK signaling pathway was involved in suppression of malignant phenotypes by silencing circ-VIM and sevoflurane treatment.
CONCLUSIONS: Silencing circ-VIM and applying sevoflurane, by separately regulating miR-124/PD-L1 axis, presented synergistic effects in inhibiting immune escape and multiple malignant phenotypes of EC cells.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Circ-VIM; Esophageal cancer; Immune escape; Lung metastases; MiR-124; PD-L1; Sevoflurane

Mesh:

Substances:

Year:  2021        PMID: 34018092     DOI: 10.1007/s10565-021-09613-0

Source DB:  PubMed          Journal:  Cell Biol Toxicol        ISSN: 0742-2091            Impact factor:   6.819


  49 in total

Review 1.  Non-coding RNA networks in cancer.

Authors:  Eleni Anastasiadou; Leni S Jacob; Frank J Slack
Journal:  Nat Rev Cancer       Date:  2017-11-24       Impact factor: 60.716

Review 2.  CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review.

Authors:  Bagher Farhood; Masoud Najafi; Keywan Mortezaee
Journal:  J Cell Physiol       Date:  2018-11-22       Impact factor: 6.384

3.  Esophageal cancer incidence and mortality in China, 2009.

Authors:  Wanqing Chen; Yutong He; Rongshou Zheng; Siwei Zhang; Hongmei Zeng; Xiaonong Zou; Jie He
Journal:  J Thorac Dis       Date:  2013-02       Impact factor: 2.895

4.  Sevoflurane inhibits the migration and invasion of colorectal cancer cells through regulating ERK/MMP-9 pathway by up-regulating miR-203.

Authors:  Lihua Fan; Yini Wu; Jianping Wang; Jiaqun He; Xin Han
Journal:  Eur J Pharmacol       Date:  2019-01-24       Impact factor: 4.432

5.  Survival after primary breast cancer surgery following propofol or sevoflurane general anesthesia-A retrospective, multicenter, database analysis of 6305 Swedish patients.

Authors:  Mats Enlund; Anders Berglund; Rebecca Ahlstrand; Jakob Walldén; Johan Lundberg; Fredrik Wärnberg; Andreas Ekman; Nina Sjöblom Widfeldt; Anna Enlund; Leif Bergkvist
Journal:  Acta Anaesthesiol Scand       Date:  2020-05-16       Impact factor: 2.105

6.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

7.  STAT3 is involved in miR-124-mediated suppressive effects on esophageal cancer cells.

Authors:  Yan Cheng; Yang Li; Yuanyuan Nian; Dong Liu; Fei Dai; Jun Zhang
Journal:  BMC Cancer       Date:  2015-04-19       Impact factor: 4.430

8.  The choice of anaesthetic--sevoflurane or propofol--and outcome from cancer surgery: a retrospective analysis.

Authors:  Mats Enlund; Anders Berglund; Kalle Andreasson; Catharina Cicek; Anna Enlund; Leif Bergkvist
Journal:  Ups J Med Sci       Date:  2014-05-26       Impact factor: 2.384

Review 9.  Circular RNAs in Cancer.

Authors:  Duc-Hiep Bach; Sang Kook Lee; Anil K Sood
Journal:  Mol Ther Nucleic Acids       Date:  2019-02-16       Impact factor: 8.886

10.  Star Circular RNAs In Human Cancer: Progress And Perspectives.

Authors:  Ye Cheng; Hanzhi Sun; Hanjin Wang; Wei Jiang; Weiwei Tang; Chen Lu; Wenling Zhang; Ziyi Chen; Chengyu Lv
Journal:  Onco Targets Ther       Date:  2019-10-07       Impact factor: 4.147

View more
  4 in total

Review 1.  Circular RNAs Involve in Immunity of Digestive Cancers From Bench to Bedside: A Review.

Authors:  Chunyue Chen; Congcong Xia; Hao Tang; Yirun Jiang; Shan Wang; Xin Zhang; Tao Huang; Xiaoqing Yuan; Junpu Wang; Li Peng
Journal:  Front Immunol       Date:  2022-04-04       Impact factor: 8.786

2.  Circular RNA hsa_circ_0000190 Facilitates the Tumorigenesis and Immune Evasion by Upregulating the Expression of Soluble PD-L1 in Non-Small-Cell Lung Cancer.

Authors:  Yung-Hung Luo; Yi-Ping Yang; Chian-Shiu Chien; Aliaksandr A Yarmishyn; Afeez Adekunle Ishola; Yueh Chien; Yuh-Min Chen; Ping-Hsing Tsai; Tzu-Wei Lin; Mong-Lien Wang; Shih-Hwa Chiou
Journal:  Int J Mol Sci       Date:  2021-12-22       Impact factor: 5.923

3.  CircRNAs as potent biomarkers in ovarian cancer: a systematic scoping review.

Authors:  Zahra Foruzandeh; Fatemeh Zeinali-Sehrig; Kazem Nejati; Dara Rahmanpour; Fariba Pashazadeh; Farhad Seif; Mohammad Reza Alivand
Journal:  Cell Mol Biol Lett       Date:  2021-09-23       Impact factor: 5.787

4.  Circular RNA SET domain protein 3 promotes nasopharyngeal carcinoma proliferation, cisplatin resistance, and protein kinase B / mammalian target of rapamycin pathway activation by modulating microRNA-147a expression.

Authors:  Gang Deng; Fei Wang; YiSa Song
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.